NDI-101150 is a highly selective, orally bioavailable small-molecule inhibitor targeting hematopoietic progenitor kinase 1 (HPK1/MAP4K1), a key negative regulator of T-cell signaling. This compound demonstrates potent immunomodulatory activity by enhancing T-cell activation and proliferation, while simultaneously exhibiting robust antitumor efficacy in preclinical models. Its mechanism of action involves disrupting HPK1-mediated suppression of immune responses, leading to improved T-cell function and sustained inhibition of tumor progression. With its favorable pharmacokinetic profile and specificity for HPK1, NDI-101150 represents a promising therapeutic candidate for cancer immunotherapy, particularly in settings where T-cell activity is compromised.
